If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
146
results.
Updated on
23/10/2026 [06:47:00]
Results 125 to 146 of 146
Absstract of: CN122628038A
The invention discloses an eutectic substance formed by combining puerarin (English name: Puerarin) and valine (English name: valine) through a non-covalent bond as well as a preparation method and application of the eutectic substance. Specifically, the invention discloses an eutectic substance formed by puerarin and valine, and the molecular formula of the eutectic substance is C21H20O9. C5H10NO2, and the molecular formula of the eutectic substance is C21H20O9. C5H10NO2. The invention relates to a preparation method of puerarin and valine eutectic. The puerarin and valine eutectic substance is applied to preparation of medicines with the effects of preventing and treating cardiovascular diseases, resisting oxidation, resisting cancer, resisting hypertension, reducing blood sugar, resisting inflammation, relieving fever, easing pain, resisting Alzheimer's disease, resisting osteoporosis and the like.
Absstract of: CN122628039A
The invention relates to a puerarin and theophylline eutectic, a preparation method, a composition and application thereof. The invention discloses an eutectic substance formed by combining puerarin (the English name is Puerarin) and theophylline (the English name is theophylline) through a non-covalent bond as well as a preparation method and application of the eutectic substance. Specifically, the invention discloses an eutectic substance formed by puerarin and theophylline, and the molecular formula of the eutectic substance is C21H20O9. C7H8N4O2; the invention discloses a preparation method of puerarin and theophylline eutectic. The puerarin and theophylline eutectic is applied to preparation of drugs with the effects of preventing and treating cardiovascular diseases, resisting oxidation, resisting cancer, resisting hypertension, reducing blood sugar, resisting inflammation, relieving fever, easing pain, resisting Alzheimer's disease, resisting osteoporosis, strengthening the heart, inducing diuresis, expanding coronary artery, relaxing bronchial smooth muscle, exciting the central nervous system and the like.
Absstract of: CN122624481A
Provided herein are methods for treating major depression or agitation associated with Alzheimer's disease comprising administering a combination therapy comprising bupropion and dextromethorphan. Concretely provided methods include administering about 105 mg bupropion hydrochloride and about 45 mg dextromethorphan hydrobromide to a human subject of about 41 years old or older age once or twice a day.
Absstract of: CN122641472A
Disclosed herein are compositions and methods for treating Alzheimer's disease with allogeneic mesenchymal stem cells. The method of treatment comprises administering a composition of allogeneic mesenchymal stem cells to a subject in need thereof, wherein the efficacy of the method of treatment can be determined by measuring specific biomarkers and improved cognitive function and/or quality of life.
Absstract of: CN122624453A
The present invention provides a pulsed release pharmaceutical composition comprising, separate or in combination, a pulsed release component comprising levodopa and a DOPA decarboxylase inhibitor for managing OFF time onset in Parkinson's disease patients.
Absstract of: CN122624617A
The invention discloses an application of leucyl phenylalanine in preparation of a medicine for treating Parkinson's disease. Specifically, it is found that the leucyl phenylalanine can relieve dopaminergic neuron dendritic degradation of a caenorhabditis elegans model of the Parkinson's disease, enhance the autophagy level and improve the proteasome activity, and an effective treatment scheme is provided for treating the Parkinson's disease.
Absstract of: CN122628001A
The invention discloses a 4-(benzo d thiazole-2-yl) benzene-1, 2-ethidene diamine compound as well as a preparation method and application of the 4-(benzo d thiazole-2-yl) benzene-1, 2-ethidene diamine compound. The structural formula of the compound is shown in the specification. Experiments prove that the compound has relatively strong ROS (Reactive Oxygen Species) removal capability and a lipid peroxidation inhibition effect; ferroptosis caused by a ferroptosis inducer can be inhibited; cerebral ischemia and nerve injury caused by cerebral ischemia can be relieved, and symptoms of neurological diseases such as Parkinson's syndrome and the like can be relieved. Therefore, the ferroptosis inhibitor designed based on the ferrostain-1/riluzole structure provided by the invention can play a synergistic effect through multiple effects to treat ferroptosis related diseases, and has the potential of being developed into a medicine for treating the ferroptosis related diseases. And the fluorescent probe can be used as an antioxidant fluorescent probe for high-sensitivity detection of ferroptosis marker lipid hydrogen peroxide (PCOOH/PEOOH), can effectively reverse the cell ferroptosis process, and has a self-indication capability. The compound is solid powder, is convenient to store and use, is simple in synthesis method, high in yield and low in cost, and has a good popularization prospect.
Absstract of: CN122641681A
The present invention relates to: an apolipoprotein E (APOE) antisense oligonucleotide; and a pharmaceutical composition for treating Alzheimer's disease comprising the same. The antisense oligonucleotide of the present invention can reduce the expression of an APOE4 variant gene, the expression of the APOE4 variant gene contributes to an increase in the risk and deterioration of Alzheimer's disease, and the antisense oligonucleotide can be used as an RNA therapeutic agent for diseases caused by abnormal levels of APOE protein or APOE variant genome expression.
Nº publicación: CN122623837A 25/08/2026
Applicant:
BIOSTIME GUANGZHOU HEALTH PRODUCT CO LTD
HEALTH AND HAPPINESS H&H HONG KONG LTD
\u5408\u751F\u5143\uFF08\u5E7F\u5DDE\uFF09\u5065\u5EB7\u4EA7\u54C1\u6709\u9650\u516C\u53F8
\u5065\u5408\u9999\u6E2F\u6709\u9650\u516C\u53F8
Absstract of: CN122623837A
The invention belongs to the technical field of nutritional compositions, and particularly relates to a nutritional composition, a nutritional composition preparation, a preparation method and application of the nutritional composition preparation and a product. The nutritional composition disclosed by the invention is prepared from phosphatidylserine, pyrroloquinoline quinone and docosahexaenoic acid, and the nutritional composition is prepared from the following components in parts by weight: 10 to 150 parts of phosphatidylserine, 10 to 30 parts of pyrroloquinoline quinone and 150 to 400 parts of docosahexaenoic acid. The composition can remarkably promote nerve growth, reduce the proportion of neuroinflammatory cells and improve the survival rate of damaged nerve cells, and has potential prevention and treatment effects on neurodegenerative diseases such as Alzheimer's disease; and the health-care tea also has wide health improvement effects of resisting aging, resisting anxiety, improving cognition and the like. On the basis, the compound can be applied to preparation of various products such as health care products, medicines and cosmetics, and a safe and effective solution is provided for preventing and treating neurodegenerative diseases, improving cognition and skin health and the like.
BOPI
Electronic site
